From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...

We need to diversify our HIV workforce with new roles that align with the health and well-being ... scientist with clinical ...

The study from Tulane University found that those living in once-redlined neighborhoods see 15% longer delays in achieving successful viral suppression of HIV compared to those in non-redlined areas.

Data from a phase Ia clinical trial of an oral, long-acting integrase inhibitor (GS-1720) in development for HIV demonstrated ...

Revolutionary new HIV drugs are being made available in 120 low-income countries, but many important populations are being left out. Sophie Cousins reports.

Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

and these new data continue to reinforce the efficacy and safety of Dovato, a two-drug regimen. “The findings from the DOLCE ...

“We are talking about sex and drugs—two topics that people call taboo,” said Brigitte Quenum, UNAIDS Regional Team Lead for ...

But Dr. Joseph McGowan, HIV services medical director at Northwell Health, said he hadn’t seen a noticeable decline in STI ...

Llama Nanobodies: A Breakthrough in Building HIV Immunity July 17, 2024 — Biology researchers have developed a new antibody therapy that can neutralize a wide variety of HIV-1 strains.